Steven Nissen

From Wikipedia, the free encyclopedia
Jump to navigation Jump to search

Steven E. Nissen (born 1948), is a cardiologist, researcher and patient advocate. He is chairman of cardiovascular medicine at the Cleveland Clinic, in Cleveland, Ohio.[1]

Joining Cleveland Clinic in 1992, Nissen served as Vice-Chairman of the Department of Cardiology (1993–2002), Section Head of Clinical Cardiology (1992–2000) and Director of the Coronary Intensive Care Unit (1992–1997). Most recently, he served as Medical Director of the Cleveland Clinic Cardiovascular Coordinating Center (C5), an organization that directs multi-center clinical trials. Nissen still attends in the Cardiac Critical Care Unit periodically throughout the year.[1]


Nissen graduated high school from the Webb School of California and pursued his undergraduate degree at the University of Michigan. He then went on to receive his medical degree from the University of Michigan School of Medicine in Ann Arbor. He completed his internal medicine internship and residency at the University of California, Davis in Sacramento, thereafter completed his cardiology fellowship at the University of Kentucky Medical Center in Lexington.[1]

Imaging technology[edit]

He produced the first images in humans in 1990 and began using IVUS to document the ubiquitous prevalence of coronary artery disease. The technology has been the basis for his research during the last decade and Nissen is currently the principal investigator for several large IVUS atherosclerosis trials.[2]


Nissen has led a number of inquiries as to the scientific integrity of many medications currently on the market. Starting with linked COX-2 inhibitors, such as Vioxx (rofecoxib) in 2001, Nissen was one of the first physicians to link it to an increased risk of heart attacks and strokes. Three years later Merck pulled Vioxx from the market when additional studies confirmed that daily, long-term use of the drug could increase the risk of heart attacks and strokes.[3]

A few years later, in 2005, Nissen re-analyzed the data related to the Bristol-Myers Squibb drug Pargluva (muraglitazar), an experimental type 2 diabetes drug. When an U.S. Food and Drug Administration (FDA) advisory panel charged with reviewing the clinical trial data approved the drug, he immediately began an in-depth analysis.[4]

In 2007, the meta-analysis by Nissen and his co-investigator Kathy Wolksi, published in the Journal of the American Medical Association online on October 20, found that the diabetes drug rosiglitazone (Avandia) produced by GlaxoSmithKline carried high cardiovascular risks,.[5] The FDA issued an alert on May 21, 2007,[6] leading to a warning by the Food and Drug Administration and a sales loss of about 75% for the drug.[7] The FDA was not made aware of the Nissen meta-analysis results until the day of its publication. In an editorial written in the Wall Street Journal, former FDA deputy commissioner Scott Gottlieb characterized the failure to inform FDA of the results in advance of publication as "upstage the FDA in an attempt to influence public debate."[8][9] BioCentury editor Steve Edelson said that congressional staffers but not the FDA had been briefed on the study results in advance.[10][11]

In November 2013, the FDA lifted its earlier restrictions on rosiglitazone after reviewing the results of the 2009 RECORD clinical trial (a six-year, open label randomized control trial), which failed to show heart infarct risks associated with the drug.[7][8]


In 2003 Nissen led a Journal of the American Medical Association study, producing evidence that five weekly infusions of ApoA-I Milano/phospholipids complex, a synthetic form of HDL, can possibly remove significant amounts of plaque from coronary arteries. The lipoprotein enhanced the ability of HDL, or “good” cholesterol to usher fat out of the arteries and into the liver for excretion leading to the purchase of Esperion Therapeutics, the tiny company that had produced recombinant Apo-A1 Milano, by Pfizer for $1.3 billion.[12]

Also in 2005, Nissen published the results of the REVERSAL trial, a headto-head comparison of the statins atorvastatin (Lipitor) and pravastatin (Pravachol). IVUS images showed that Lipitor had effectively halted the progression of plaque buildup, but coronary disease progressed considerably in those given Pravachol. The study suggested that treatments should aim to lower LDL, or “bad” cholesterol levels as much as possible.[13]

In 2006, Nissen and his co-investigators reported on The ASTEROID trial (A Study to Evaluate the Effect of Rosuvastatin On Intravascular Ultrasound-Derived Coronary Atheroma Burden). The study concluded that intensive use of statins resulting in a decreased LDL and increased HDL can reverse the build-up of plaque in coronary arteries, as measured by IVUS.[14]


  • Served the U.S. Food and Drug Administration as member of the CardioRenal Advisory Panel from 2000 until 2005, serving as Chairman for final year of his appointment.
  • Testified before Congress and serves as a resource to several key members of Congress on health care related issues.

Conflict of Interest[edit]

There have been allegations about Nissen's potential conflict of interest.[15]

Awards and recognitions[edit]

  • In 2007, he was named one of the 100 Most Influential People in the world (Time 100) by Time Magazine.[16]
  • Outstanding Teacher Award by the Cleveland Clinic Fellows in Cardiovascular Medicine in 2004, 1998, and 1993.[1]
  • Gill Heart Institute Award of the University of Kentucky for Outstanding Contributions to Cardiovascular Research in 2004.[1]



  1. ^ a b c d e f Steven Nissen MD, physician profile [1], Cleveland Clinic, retrieved 2/2010
  2. ^ Nissen SE, Gurley JC, Grines CL, Booth DC, McClure R, Berk M, Fischer C, DeMaria AN (1991). "Intravascular ultrasound assessment of lumen size and wall morphology in normal subjects and patients with coronary artery disease". Circulation. 84 (3): 1087–1099. doi:10.1161/01.cir.84.3.1087. PMID 1884441.
  3. ^ Mukherjee D, Nissen SE, Topol EJ (2001). "Risk of cardiovascular events associated with selective COX-2 inhibitors". JAMA. 286 (8): 954–959. doi:10.1001/jama.286.8.954. PMID 11509060.
  4. ^ Nissen SE, Wolski K, Topol EJ (2005). "Effect of muraglitazar on death and major adverse cardiovascular events in patients with type 2 diabetes mellitus". JAMA. 294 (20): 2581–6. doi:10.1001/jama.294.20.joc50147. PMID 16239637.
  5. ^ Nissen SE, Wolski K (2007). "Effect of rosiglitazone on the risk of myocardial infarction and death from cardiovascular causes". N Engl J Med. 356 (24): 2457–71. doi:10.1056/NEJMoa072761. PMID 17517853.
  6. ^ "FDA News Release: FDA Issues Safety Alert on Avandia". 2007-05-21. Retrieved 2010-02-17.
  7. ^ Saul, Stephanie (2007-07-22). "Drug Safety Critic Hurls Darts From the Inside". The New York Times. Retrieved 2010-02-17.
  8. ^ "Journalistic Malpractice - WSJ".
  9. ^ "Safety of Rosiglitazone Maleate (Avandia)".
  10. ^ "Avandia and 9/11 -".
  12. ^ Nissen SE, Tsunoda T, Tuzcu EM, Schoenhagen P, Cooper CJ, Yasin M, Eaton GM, Lauer MA, Sheldon WS, Grines CL, Halpern S, Crowe T, Blankenship JC, Kerensky R (2003). "Effect of recombinant ApoA-I Milano on coronary atherosclerosis in patients with acute coronary syndromes: a randomized controlled trial". JAMA. 290 (17): 2292–300. doi:10.1001/jama.290.17.2292. PMID 14600188.
  13. ^ Nissen SE (2003). "Halting the progression of atherosclerosis with intensive lipid lowering: results from the Reversal of Atherosclerosis with Aggressive Lipid Lowering (REVERSAL) trial". Am J Med. 118 (Suppl 12A): 22–7. doi:10.1016/j.amjmed.2005.09.020. PMID 16356804.
  14. ^ Nissen SE, Nicholls SJ, Sipahi I, Libby P, Raichlen JS, Ballantyne CM, Davignon J, Erbel R, Fruchart JC, Tardif JC, Schoenhagen P, Crowe T, Cain V, Wolski K, Goormastic M, Tuzcu EM; ASTEROID Investigators. (2006). "Effect of very high-intensity statin therapy on regression of coronary atherosclerosis: the ASTEROID trial". JAMA. 295 (13): 1556–65. doi:10.1001/jama.295.13.jpc60002. PMID 16533939.CS1 maint: Multiple names: authors list (link)
  15. ^ "Steven Nissen, Conflicts Of Interest, And The New Cholesterol Drugs". Forbes. June 12, 2015.
  16. ^ Steven Nissen - The Time 100